EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Characterizing cutaneous leishmaniasis in a conflict-affected region: a study from North Waziristan, Pakistan

Zahid Ullah iD, Fazeelat Samad iD, Rahila Bano iD, Sarah Arif iD, Sher Zamir iD, Nighat Aziz iD, Hassan Khan iD

Turkish Journal of Medical Sciences · 12.12.2023 · 53 (6) · 1767-1775

DOI: 10.55730/1300-0144.5746 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 12.12.2023. Verfasst von Zahid Ullah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Gomal Medical College, Dera Ismail Khan, Pakistan. Hauptthemen laut MEDLINE: Leishmaniasis, Cutaneous. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/aim: Cutaneous leishmaniasis is an emerging tropical disease that remains a serious public health issue in Pakistan, particularly in North Waziristan. The current research was carried out to investigate the presence of cutaneous leishmaniasis in this region. Materials and methods: This prospective observational study was conducted from October 2018 to December 2020 at District Head Quarter Hospital Miranshah in North Waziristan with the collaboration of the Pathology Department of Gomal Medical College Dera Ismail Khan, Khyber Pakhtunkhwa. Needle aspirates were used for the microscopic Giemsa-stained slides. SPSS was used for data analysis.

Results

Of the 5406 clinically-suspected cases, 2603(48.2%) were positive by microscopic examination. Of these 2603 patients, 1474 (57%) were male and 1129 (43%) were female. Most of the lesions were on the face, followed by upper and lower limbs. The 5-10-year age group had the highest percentage of 1167 (45%). A single lesion affected 96.6% of the patients, while 2.7% had double lesions and 0.7% had triple lesions. A high number of cutaneous leishmaniasis were seen from April to August, while the lowest number was seen November to December.

Conclusion

This study provides extensive information in relation to the existence of cutaneous leishmaniasis in the North Waziristan district of Pakistan, as well as the detailed demographic features of those affected by the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leishmaniasis, CutaneousHumansPakistanMaleFemaleChildProspective StudiesAdultAdolescentChild, PreschoolYoung AdultMiddle AgedInfantArmed ConflictsAged

Stichwörter der Autor:innen

Leishmania tropicaNorth WaziristanPakistancutaneous leishmaniasis

Autor:innen und Institutionen

  • Department of Pathology, Gomal Medical College, Dera Ismail Khan, Pakistan.
  • Department of Physiology, Gomal Medical College, Dera Ismail Khan, Pakistan.
  • Department of Pharmacology, Gomal Medical College, Dera Ismail Khan, Pakistan.
  • Faculty of Pharmacy, Gomal University, Dera Ismail Khan, Pakistan.

ORCID-Profile: Zahid Ullah, Fazeelat Samad, Rahila Bano, Sarah Arif, Sher Zamir, Nighat Aziz, Hassan Khan

Zitieren

APA

Ullah, Z., Samad, F., Bano, R., Arif, S., Zamir, S., Aziz, N., & Khan, H. (2023). Characterizing cutaneous leishmaniasis in a conflict-affected region: a study from North Waziristan, Pakistan. Turkish Journal of Medical Sciences, 53(6), 1767-1775. https://doi.org/10.55730/1300-0144.5746

Vancouver

Ullah Z, Samad F, Bano R, Arif S, Zamir S, Aziz N, et al. Characterizing cutaneous leishmaniasis in a conflict-affected region: a study from North Waziristan, Pakistan. Turkish Journal of Medical Sciences. 2023;53(6):1767-1775. doi:10.55730/1300-0144.5746

BibTeX
@article{Ullah2023,
  author = {Ullah, Zahid and Samad, Fazeelat and Bano, Rahila and Arif, Sarah and Zamir, Sher and Aziz, Nighat and Khan, Hassan},
  title = {Characterizing cutaneous leishmaniasis in a conflict-affected region: a study from North Waziristan, Pakistan},
  journal = {Turkish Journal of Medical Sciences},
  year = {2023},
  volume = {53},
  number = {6},
  pages = {1767--1775},
  doi = {10.55730/1300-0144.5746}
}
Kostenlos starten →